SCROLL NEWS / DISCOVERY

Search headlines

Find the stories shaping the conversation.

Search mode
Refine results
Active filters Keyword All time

Results for " Biotech " 274 found 🔀 AI-powered Shuffle

Wilmington health tech founder launches new venture

Several years after launching his health tech startup Artemis Immersive, founder Adam Isley is setting his sights on new horizons. Co-founded in 2023 by husband-and-wife Adam Isley and Kaylan Barbrey, along with Matthew Raffa and Bill Blakesley, Artemis Immersive began as a spatial medtech company that created digital renderings of medical scans for viewing in augmented reality (AR). Isley said the firm, which won an NC Tech award in the Biotech + HealthTech Innovation category last year, has raised $1.2 million in total in seed funding since launching. Isley has since created a new venture, Research and Me, building on the Artemis platform. Like Artemis Immersive’s core software, VoxScan, Research and Me combines health data with artificial intelligence in a 3D interactive environment to help patients better understand health outcomes and provide integrative wellness support. While the Artemis product is no longer Isley’s primary focus, he said the company’s technology and ambitions have evolved into different ventures, like Research and Me. "It's a different venture building on the Artemis platform, and there'll probably be more,” Isley said. He added, "I was very disappointed in the quality of the information available to general patients about their healthcare... I wanted to give patients more and a better plate of choices." Research and Me is still in its beta phase, Isley said, with usability testing ongoing in partnership with the firm’s partner, Medicap Pharmacy and Wellness Center, owned by Barbrey. "As someone who's kind of dedicated their life to working in healthcare, I've tried to bring this spirit and passion to it,” he said, “and a lot of the resources that we'll be providing are free — like a base level of free care for any patients, or medical education if they've got specific conditions." Isley describes Research and Me as a “patient-first” platform designed to securely store and pseudonymize health data and use AI and medical literature to generate insights. The insights are presented in an interactive 3D environment for patients and providers to explore conditions, treatments and wellness plans together. "It's almost like a democratization of understanding medical information," Isley said. "We take a whole bunch of clinical data, we take a whole bunch of peer‑reviewed, published studies on PubMed, and we try to turn them into chunks of information that normal humans can understand." Like VoxScan, the Research and Me platform lets users interact with 3D anatomical models for visualization. The platform provides a space for tracking, notes and insights. The platform also supports video conferencing, Isley said, allowing providers or coaches to examine models and data together. "We wanted to create a safe environment where you can start to learn and experiment with new features about your health, using agents to do that,” Isley said. While Research and Me is in beta-phase testing with Medicap Pharmacy, Isley said he envisions the platform serving a wellness-oriented community, working with sports performance clinics and hormone optimization. Isley, who is working towards a wellness-coach board certification, also plans to offer functional wellness consults through the platform. Long‑term, Isley says he wants the platform to embody an “integrative health practitioner” approach, “connecting experts of different fields and specializations in a way that they can make a greater impact in people's lives.” “For people in the state of North Carolina, it's already a win,” Isley said of the Medicap rollout, noting that partner clinics get “immediate resources for learning about their health and wellness conditions… out of the box.” Isley plans to launch Research and Me’s provider portal in 2028 and begin pursuing integrations with larger systems, he said.

wilmingtonbiz.com logo
Sep 11 • 1:12 PM EDT • Health • wilmingtonbiz.com
As elective surgical volumes drag in 2026, health system execs say solid demand is still in sight

Though surgical volumes were a sore spot for major for-profit health systems in the opening half of 2026, executives said this week they are optimistic those service lines will stay afloat for the | In fireside chats this week, leaders of the country's largest for-profit systems acknowledged a slowdown in demand that will generally continue through 2026. They also affirmed continued investments to meet future anticipated demand, particularly in ambulatory settings.

fiercehealthcare.com logo
Sep 10 • 9:00 AM EDT • Health • fiercehealthcare.com
AI and Biotechnology Risks Demand Science Diplomacy

Track-two science diplomacy can provide vital safeguards on AI.

foreignpolicy.com logo
Sep 10 • 8:00 AM EDT • Science • foreignpolicy.com
The Escalator: Inizio, Health Catalyst, Eversana and more

See which leaders are on the move across the pharma, biotech and medical marketing industries.

mmm-online.com logo
Sep 10 • 8:00 AM EDT • Health • mmm-online.com
A booming business on Wall Street would love more biotechs to quietly die

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality shell companies to meet the demand.

biopharmadive.com logo
Sep 10 • 3:45 AM EDT • Business • biopharmadive.com
Luma locks down 15-year, $410M fund for life science investments

Luma Group today announced the final close of its inaugural life sciences venture capital fund, totaling $410 million. The New York-based investment firm has had a grip on life sciences since its founding in 2023. The funds unveiled today, dubbed LumaBio Fund I, include investments that have already been made into more than 10 biotechs. They include the likes of eye disease-focused Character Biosciences, rebranded Belgian biotech Coultreon Biopharma and cellular rejuvenation company Altos Labs. The fund saw early success when one of the companies it co-founded, called Vaccine Company, was picked up by Eli Lilly earlier this year for up to $1.55 billion. The acquisition of the in vivo nanoparticle technology-focused biotech formed part of a trio of vaccine buys for the Big Pharma, which has itself been on a prolonged spending spree in 2026. Luma's fund is structured as a 15-year investment with plans to support groundbreaking science and support companies through key milestones from discovery to commercialization, Luma explained in the release. "We founded Luma Group on the belief that extraordinary science, supported by patient, long-term capital, has the power to improve millions of lives," Joshua Fink, founder and managing member of Luma Group, said in the release. "This fund represents more than capital—it is a commitment to partnering with extraordinary innovators as they translate visionary science into life-changing medicines."

fiercebiotech.com logo
Sep 9 • 9:43 AM EDT • Science • fiercebiotech.com
SC's Emerging Biotech Industry Receives National Recognition

Genetic Engineering & Biotechnology News (GEN) recently named the Palmetto State among its “Regional and State Clusters to Watch” in its first-ever Next 10 U.S. Biopharma Clusters report, highlighting emerging life sciences ecosystems beyond...

greenvillebusinessmag.com logo
Sep 8 • 10:39 AM EDT • Business • greenvillebusinessmag.com
Osaka has the science. Now it needs the business

Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.

pharmaceutical-technology.com logo
Sep 8 • 5:13 AM EDT • Science • pharmaceutical-technology.com
Osaka has the science. Now it needs the business

Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.

medicaldevice-network.com logo
Sep 8 • 5:13 AM EDT • Science • medicaldevice-network.com
Osaka has the science. Now it needs the business

Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.

pharmaceutical-technology.com logo
Sep 8 • 5:13 AM EDT • Business • pharmaceutical-technology.com
Osaka has the science. Now it needs the business

Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.

medicaldevice-network.com logo
Sep 8 • 5:13 AM EDT • Business • medicaldevice-network.com
Merrimack Anheuser-Busch Property purchased by United Therapeutics Corporation

Biotechnology firm United Therapeutics Corporation has acquired the former Anheuser-Busch brewery site in Merrimack for $47 million, according to sources familiar with the matter. The transaction secures one of Southern New Hampshire’s largest industrial parcels, spanning nearly 300 acres off Daniel Webster Highway

nhbr.com logo
Sep 6 • 11:33 AM EDT • Business • nhbr.com
Deep dive
😐 Neutral (9%)
wow
56%
ahah
22%
love
22%
Billionaire family offices back health care and biotech startups in August

The personal investment firms of titans like Stanley Druckenmiller are backing innovations in gene editing, drug discovery and more.

cnbc.com logo
Sep 3 • 8:00 AM EDT • Health • cnbc.com
NSF launches three new Science and Technology Centers with $90M investment in transformative research

The U.S. National Science Foundation is investing $90 million over five years to support three new NSF Science and Technology Centers (NSF STC). These centers will advance American leadership in science and technology, strengthen the nation’s STEM workforce, and accelerate innovation in fields ranging from artificial intelligence and biotechnology to fusion energy and robotics., , , , The three centers will bring together researchers from universities, national laboratories, industry, and oth...

webwire.com logo
Aug 31 • 8:00 PM EDT • Science • webwire.com
Rice-developed BuoyBeads bring biotechnology lessons to high school classrooms

A biotechnology kit developed at Rice allows high school students to create living materials.

news.rice.edu logo
Aug 31 • 8:00 AM EDT • Science • news.rice.edu
Empowering Young Scientists: Caldwell University’s Biotechnology Research Fellowship Program Completes Its Second Year

Caldwell, NJ – Caldwell University’s Biotechnology Research Fellowship Program completed its second year on Friday, August 14, 2026. This dynamic, three-week intensive placed high school fellows directly into the world […]

caldwell.edu logo
Aug 28 • 2:46 PM EDT • Science • caldwell.edu
Deep dive
😐 Neutral (15%)
love
50%
wow
50%
Boston Scientific hit by cyberattack causing ‘disruptions’ to parts of its business

This year has seen a growing number of medtechs hit by cyberattacks, and now Boston Scientific has become the latest victim. In an SEC filing posted Aug. 26, the medtech giant said it had detected a “cybersecurity incident” the day before. The incident has affected certain parts of its information technology systems, something that “has resulted in a global disruption to the company’s operations.” The incident has hit not just its information systems but also its business applications, which “support aspects of the Company’s operations,” it said in the filing. This includes its ability to process and ship customer orders. Boston Scientific said it is working to restore the systems, but the timeline remains unknown. Related Baylor Genetics hit by cybersecurity attack targeting patient, staff information As the company investigates the incident, it remains unclear how significantly its business will be affected. “Accordingly, the Company has not yet determined whether the incident is reasonably likely to have a material impact.” The company’s shares were down 3.5% in premarket trading as the news broke. This adds another layer of pressure for the medtech, which last month revealed a new global restructuring program that starts this year and is slated to be completed by 2029. The company said at the time that it “does expect some headcount reductions to result from these restructuring activities,” but did not provide any numbers or specify areas where the cuts may be made. It added, however, that new jobs are also set to be “created in areas of growth.” It was also forced to cut its sales guidance in Q2, saying in late July that it now expects full-year 2026 organic revenue growth of 5% to 6%, down from its previous guidance of 6.5% to 8%. Boston Scientific is one of a growing number of life sciences companies, notably medtechs, that have been hit by cyberattacks this year. These include Abbott, iRhythm, Medtronic and Stryker, as well as Big Pharmas Amgen and Novo Nordisk.

fiercebiotech.com logo
Aug 26 • 7:26 AM EDT • Business • fiercebiotech.com
N.C. A&T’s Honors College Hosts 2026 Honda STEM Summer Camp on Biotechnology, Data Science

N.C. A&T’s inaugural Honda STEM Summer Camp gave 29 students hands-on experience in biotechnology, data science, AI and emerging technologies through research, mentorship and industry engagement.

ncat.edu logo
Aug 18 • 8:00 AM EDT • Science • ncat.edu
Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Harlan Robins (Photo via Harell Data) Harlan Robins spent years as the co-founder and chief scientific officer of Adaptive Biotechnologies, helping build

geekwire.com logo
Aug 17 • 8:15 PM EDT • Science • geekwire.com
After program reductions, Calvin University debuts engineering, computer science school

The school is expected to enhance core offerings in fields like biotechnology and artificial intelligence.

mlive.com logo
Aug 16 • 9:00 AM EDT • Science • mlive.com
Pace appoints Andy Fenny as president to drive life science growth

Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.

thepharmaletter.com logo
Aug 13 • 8:00 PM EDT • Science • thepharmaletter.com
Screwworm neutralizer: insect sterilization | Investors Lab

The fight against screwworm has moved beyond traditional government programs into an arena ripe for biotech intervention:

sciencenews.org logo
Aug 12 • 7:00 AM EDT • Science • sciencenews.org
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

/PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the...

prnewswire.com logo
Aug 11 • 7:30 AM EDT • Business • prnewswire.com
Deep dive
😐 Neutral (4%)
wow
70%
sad
30%
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice

AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.

fiercebiotech.com logo
Aug 10 • 8:24 AM EDT • Health • fiercebiotech.com
Supporters of a bipartisan bill say America’s biotechnology future depends on measurement science

I think the success will be that there are uniform standards that could be used by AI, by international scientists," said Congresswoman April McClain Delaney.

federalnewsnetwork.com logo
Aug 6 • 2:55 PM EDT • Science • federalnewsnetwork.com
Viewpoint: Europe needs a new scientific contract

The White House's new science strategy should be required reading in the Berlaymont and every European capital.Not because Europe should copy it. Parts of it should concern Europeans deeply. But because it asks the question Europe has so far avoided while steadily losing ground in the global race for technological leadership.Europe already possesses many of the world's finest universities, scientists and research-intensive companies. It produces world-leading research in fields ranging from quantum technologies and biotechnology to climate science. Yet time and again Europe generates the scientific breakthroughs while others build the companies, industries and strategic advantages around them, particularly in digital technologies. Increasingly, we find ourselves regulating technologies whose underlying capabilities were developed elsewhere.This is not primarily a scientific failure. It is an institutional one.The settlement that shaped modern science policy emerged after the Second World War. In Science, the Endless Frontier, Vannevar Bush argued that governments should invest in fundamental research while protecting scientists from political direction. Public investment was justified precisely because no government, university or company could predict where the next transformative discovery would emerge.That scientific contract served liberal democracies extraordinarily well. It underpinned decades of advances in medicine, computing, energy and communications, but the world for which it was designed no longer exists.Artificial intelligence is transforming not only technology but the production of knowledge itself. Advanced chips, computing power, data and scientific instruments have become strategic assets. Scientific knowledge now diffuses globally almost instantly. Competitive advantage increasingly lies not in making discoveries first, but in possessing the infrastructure, capital, engineering capability and institutions required to translate those ideas into products, industries and strategic advantage.The old boundaries between science, industrial policy, national security and geopolitics have largely disappeared. Dual-use technologies now underpin both economic power and military deterrence.The US has recognised this shift. In July, the White House published Science: A New Golden Age, a comprehensive attempt to rethink the relationship between science and national power. The report builds on Bush's legacy, but departs from his framework in important ways. Science is no longer treated simply as the source of future discoveries. It is presented as the foundation of economic resilience, technological leadership and national security. AI, advanced infrastructure and the capacity to build become as important as discovery itself.Yet the report also reveals a striking paradox. The same administration calling for “a new golden age” of US science has simultaneously proposed deep cuts to the federal research enterprise while expanding political influence over the allocation of public research funding. Europe should therefore distinguish between the report's diagnosis and its prescription. The diagnosis, that science has become a strategic asset, is compelling. But the prescription is self-defeating. Long-term technological leadership depends on strong universities, academic freedom and the institutional autonomy that makes scientific discovery possible. This distinction matters. Bush's achievement was never simply to make science serve national strength. It was to establish a division of labour in which governments invested in research without attempting to direct discovery itself. Scientific breakthroughs emerge precisely because researchers retain the freedom to pursue questions whose value cannot yet be demonstrated and whose conclusions cannot be anticipated.Neither China, nor the USAs science becomes more strategically important, the temptation to politicise it inevitably grows. But scientific freedom is not an obstacle to technological leadership, it is an essential precondition.China represents the opposite model. For decades it has integrated science, manufacturing, infrastructure and industrial policy into a single national strategy. Its ability to mobilise resources around critical technologies is formidable. But it does so within an authoritarian system where scientific priorities are increasingly inseparable from political power.Europe should imitate neither model. It should learn from the strategic ambition of the US without importing its growing politicisation of science. And it should learn from China's capacity to build without adopting its concentration of power.Instead, Europe needs a scientific contract of its own. Bush's scientific contract protected the freedom to discover because the defining challenge of the 20th century was producing new knowledge. Europe's next scientific contract must preserve that freedom while ensuring that scientific discoveries can be converted into technological, industrial and strategic capability. Because in a transactional world, Europe's freedom to shape its own future depends on its capacity to build it.Related articlesThe US ‘golden age’ science strategy: what Europeans need to knowEuropean researchers sound the alarm that Trump rule changes will hit cooperationNIH turmoil risks reciprocal EU-US access to health research fundingThis does not mean subordinating free science to competitiveness or industrial policy. On the contrary. Scientific autonomy remains the first principle of Europe's next scientific contract. Governments should not direct scientific discovery. Their responsibility is to ensure that Europe's scientific, industrial, financial and regulatory institutions work together rather than in isolation.Meeting that responsibility requires far more than research funding. European researchers need access to world-class computing infrastructure, advanced laboratories, shared datasets and scientific facilities. Innovative companies need patient capital, testing environments and a genuine single market in which they can scale without facing 27 different regulatory regimes. Public procurement must evolve from purchasing existing technologies to creating markets for new ones. Regulators must become partners in experimentation rather than guardians of yesterday's rules.A connecting architectureEurope does not need to invent the Defense Advanced Research Projects Agency (Darpa) model from scratch. Britain's Aria, Germany's Sprind and Wellcome Leap already show that Europe can build institutions capable of taking high-risk, mission-oriented bets while preserving democratic accountability. The challenge now is not to create more isolated initiatives, but to connect them to Europe's broader scientific, industrial and financial system so that breakthrough discoveries can scale.Above all, Europe must stop treating research, innovation, industrial policy, finance and security as separate policy domains. The challenge is no longer to create excellent institutions in each of these fields, but to make them work as one European innovation system. Europe's strength will increasingly depend not on excellence within institutions, but on excellence across them.Europe's ambition should be neither to imitate the US nor to emulate China. It should demonstrate that scientific freedom, democratic legitimacy and technological capability are not competing objectives, but mutually reinforcing strengths. In an age of geopolitical rivalry, Europe's greatest advantage may ultimately be its ability to attract the world's best talent by combining scientific freedom, democratic openness and technological ambition.Bush's scientific contract helped define the 20th century because it protected the freedom to discover. Europe's challenge is not to abandon that achievement but to extend it. The defining task of Europe's next scientific contract is to preserve the freedom to discover while building Europe's capacity to translate scientific discovery into technological power.Kaare Nielsen is founder of Pomus, a Danish think tank on science and innovation.

sciencebusiness.net logo
Aug 5 • 8:00 PM EDT • Science • sciencebusiness.net
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’

Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.

fiercebiotech.com logo
Aug 5 • 2:50 PM EDT • Business • fiercebiotech.com
Scientists use gene editing to create hypoallergenic dogs

Scientists at a biotech company have used gene editing to create two hypoallergenic beagles that don't trigger allergies.

apnews.com logo
Aug 5 • 7:00 AM EDT • Technology • apnews.com
High-Signal Publisher
Senate Panel To Examine Biotech's Role in U.S. Health Resilience

Senate Finance Committee investigates biotech's impact on U.S. health resilience as China gains pharmaceutical advantage. Hear expert testimony August 4.

legis1.com logo
Aug 2 • 8:24 AM EDT • Health • legis1.com
😐 Neutral (0%)
ahah
67%
wow
33%
FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.

npr.org logo
Aug 1 • 7:00 AM EDT • Technology • npr.org
High-Signal Publisher
Biotech is Back: A Wave of Life Science Deals is Pumping Cash into the Sector

Learn more about the latest updates in legal, with expert commentary and insights from trusted attorneys from Foley Hoag LLP. Foley Hoag is a professional community of highly qualified attorneys from all over the US.

foleyhoag.com logo
Jul 31 • 8:00 AM EDT • Science • foleyhoag.com
AI Cognitive Health Startup Mantis Biotech Rethinks How Women Are Diagnosed

The AI Catching Brain Fog, ADHD, And Dementia Between Doctor Visits

forbes.com logo
Jul 31 • 7:00 AM EDT • Health • forbes.com
Killing slime: an AI-first biotech solution | Investors Lab

We love public science lessons, like the algae debacle that turned Washington, D.C.'s Lincoln Memorial Reflecting Pool a vibrant green this summer after a renovation. It's not exactly a new development. Algal blooms have intermittently plagued the site for generations, including during the last big overhaul in 2012. But the latest episode lingers despite treatments with hydrogen peroxide and an ozone nanobubble system. As Bethany Brookshire makes clear for Science News, there's another option that might have managed the crisis far more effectively, had it been used from the start.

sciencenews.org logo
Jul 29 • 9:30 AM EDT • Science • sciencenews.org
The VA could help America win the biotechnology race with China

“Together, HHS, the VA, and the DOD form a strong American innovation ecosystem — one that China and other competitors cannot easily replicate,” writes former VA Secretary David Shulkin.

statnews.com logo
Jul 29 • 4:30 AM EDT • Health • statnews.com
Why 3 secretive biotechs are keeping their science close to the chest

Startups like Altos Labs are keeping pipeline details scarce to protect their ideas from competitors — but some experts say stealth only works for biotechs with deep pockets.

pharmavoice.com logo
Jul 27 • 5:36 AM EDT • Science • pharmavoice.com
FDA rejects application for new oral MR imaging contrast agent

Biotechnology firm Ascelia Pharma is working to roll out Orviglance, a novel manganese-based product for visualizing focal liver lesions during MRI, but faced a recent setback.

radiologybusiness.com logo
Jul 26 • 7:55 PM EDT • Business • radiologybusiness.com
Biotech is ‘leading innovative science, not universities’

Sharper mission and team ethos of pharma companies make them more effective than university labs, says Nobelist Fred Ramsdell

timeshighereducation.com logo
Jul 26 • 7:01 PM EDT • Science • timeshighereducation.com
Girl, 6, Died After Experimental Gene-Editing Treatment in China: Science

A young girl died after receiving an experimental gene-editing treatment in a clinical trial in Shanghai, Science reported, raising questions about regulatory oversight and transparency as China rapidly expands its biotechnology ambitions.

bloomberg.com logo
Jul 23 • 11:11 PM EDT • Science • bloomberg.com
Biotech experts want FDA drug reviews based on science, not politics

Biotech experts call for the FDA to prioritize scientific expertise over political influence in drug reviews amid recent leadership changes and staffing challenges.

journalrecord.com logo
Jul 22 • 3:53 PM EDT • Politics • journalrecord.com
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS

/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

prnewswire.com logo
Jul 22 • 8:30 AM EDT • Health • prnewswire.com
Deep dive
😐 Neutral (10%)
ahah
50%
wow
50%
Biotech experts want FDA drug reviews based on science, not politics

Biotech experts and industry executives are calling plans by the U.S. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want ​assurance that politics will not interfere in the agency's drug-review process.

reuters.com logo
Jul 22 • 6:06 AM EDT • Science • reuters.com
Biotech experts want FDA drug reviews based on science, not politics

Biotech experts and industry executives are calling plans by the U.S. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want ​assurance that politics will not interfere in the agency's drug-review process.

reuters.com logo
Jul 22 • 6:06 AM EDT • Politics • reuters.com
Biotech experts want FDA drug reviews based on science, not politics

July 22 (Reuters) - Biotech experts and industry executives are calling plans by the U. Food and Drug Administration — hit by job cuts last year — to hire thousands of employees and update clinical-trial standards encouraging, but want assurance that politics will not interfere in the agency's drug-review process.

finance.yahoo.com logo
Jul 22 • 6:06 AM EDT • Science • finance.yahoo.com
Gov. Shapiro highlights life sciences growth with visit to Philadelphia biotech incubator

The $125 million Innovate in PA 2.0 initiative aims to help startups grow, commercialize new technologies and keep life sciences companies in Pennsylvania.

whyy.org logo
Jul 21 • 3:35 PM EDT • Science • whyy.org
Rebuilding the Innovation Engine: How We Got Here And What Comes Next

Federal investment in basic science built America’s innovation engine, but declining support is threatening U.S. leadership, writes Dietrich Stephan, Ph.D.

lifescienceleader.com logo
Jul 20 • 1:38 AM EDT • Science • lifescienceleader.com
Deep dive
😐 Neutral (16%)
ahah
40%
wow
37%
love
23%
Harvard Scientists Turned a Silicon Chip Into a DNA Factory

Harvard scientists have built a silicon chip that writes DNA using electricity and water, pointing toward a cleaner future for DNA manufacturing and biotechnology.

scitechdaily.com logo
Jul 19 • 5:57 PM EDT • Science • scitechdaily.com
Merck’s cholesterol pill gets US FDA approval

Merck said on Thursday the U.S. FDA has approved its cholesterol pill, the first of its kind to receive the health regulator’s ​nod, bolstering the drugmaker’s efforts to diversify beyond its blockbuster ‌cancer treatment Keytruda.

cnn.com logo
Jul 16 • 7:38 AM EDT • Health • cnn.com
The opioid offensive: Fighting fentanyl | Investors Lab

As the clinical-stage biotech sector tackles this multibillion dollar public health imperative, a mix of established players and venture-backed innovators are making strides:

sciencenews.org logo
Jul 15 • 4:52 PM EDT • Science • sciencenews.org
AB Science ends three studies in multiple sclerosis, other immune conditions

The trials, which were testing the tyrosine kinase inhibitor masitinib, had previously been paused. AB Science’s decision not to resume them was a matter of prioritization, not safety, the biotech said.

biospace.com logo
Jul 13 • 7:32 AM EDT • Science • biospace.com
😐 Neutral (7%)
ahah
57%
wow
43%
AB Science cuts three trials in pipeline reset

French biotech AB Science is discontinuing three masitinib trials as it concentrates its clinical resources on an ALS phase 3 programme and the early-stage development of AB8939 in acute myeloid leukaemia.

european-biotechnology.com logo
Jul 13 • 4:12 AM EDT • Science • european-biotechnology.com
DGIST secures four projects under the Ministry of Science and ICT’s Group Research Support Program, spanning basic science to cutting-edge deep tech

- DGIST secured one Science Research Center (SRC) project and three Basic Research Laboratory (BRL) projects, taking the lead in addressing national challenges in science and technology - DGIST reaffirms its world-class convergence research capabilities spanning AI, robotics, and advanced biotechnology

asiaresearchnews.com logo
Jul 12 • 9:49 PM EDT • Science • asiaresearchnews.com
Scientists enable DNA synthesis using only temperature instead of chemical reagents

"Complex chemical processes are essential for making DNA." This long-held assumption in the field of biotechnology has been overturned by a Korean research team. A KAIST research team has developed the ...

phys.org logo
Jul 7 • 9:20 AM EDT • Science • phys.org
Inside the BoF and Clinuvel Community Lunch Exploring the Future of Skin Health

Investors from Goldman Sachs, L Catterton and Bansk Beauty joined leaders from L’Oréal, Harrods, Space NK and Unilever at The Business of Beauty Global Forum to examine how advances in medicine, biotechnology and longevity are redefining the future of skin health.

businessoffashion.com logo
Jul 7 • 12:00 AM EDT • Health • businessoffashion.com
Inside the BoF and Clinuvel Community Lunch Exploring the Future of Skin Health

Investors from Goldman Sachs, L Catterton and Bansk Beauty joined leaders from L’Oréal, Harrods, Space NK and Unilever at The Business of Beauty Global Forum to examine how advances in medicine, biotechnology and longevity are redefining the future of skin health.

businessoffashion.com logo
Jul 7 • 12:00 AM EDT • Business • businessoffashion.com
Startups move to Colorado amid concerns state losing its luster for tech companies

A biotech startup and an aerospace startup said their moves to Colorado were based on lifestyle issues and the state’s business climate.

denverpost.com logo
Jul 6 • 8:00 AM EDT • Business • denverpost.com
From recombinant DNA to AI: Who gets a say in powerful new science?

Professor Luis Campos studies the history of biology and biotechnology.

news.rice.edu logo
Jul 6 • 8:00 AM EDT • Science • news.rice.edu
Claude Science: What Anthropic's New Research Workbench Actually Does for Oncology

Claude Science: What Anthropic's New Research Workbench Actually Does for Oncology /

oncodaily.com logo
Jul 5 • 10:29 AM EDT • Science • oncodaily.com
Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

finance.yahoo.com logo
Jul 5 • 9:35 AM EDT • Health • finance.yahoo.com
Vanguard Health Care vs. iShares Biotech: How Do These ETFs Stack Up?

Broad healthcare diversification or concentrated biotech growth? Compare cost, risk, and portfolio composition to find your fit.

finance.yahoo.com logo
Jul 4 • 9:35 AM EDT • Health • finance.yahoo.com
Xtalks Announces its Life Science Webinar Calendar for July 2026

Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

finance.yahoo.com logo
Jul 3 • 1:55 PM EDT • Science • finance.yahoo.com
SPDR Health Care ETF Tops iShares Biotech in Long-Term Returns

Compare portfolio diversity, risk profiles, and income potential as you weigh these two leading healthcare ETFs.

finance.yahoo.com logo
Jul 2 • 8:05 AM EDT • Health • finance.yahoo.com
Middle School Students Conduct Summer Science Experiments at USU STARS GEAR UP Biotechnology Camp

Utah middle school students from Sanpete County gained hands-on STEM experience during a two-day Biotech camp in June.

usu.edu logo
Jul 1 • 8:00 PM EDT • Science • usu.edu
Exploring STEM Futures through UConn 4-H’s Biotechnology Club

The Biotechnology Club is intentionally designed to complement classroom learning and prepare Connecticut students to enter the skilled, science-literate wo ...

today.uconn.edu logo
Jul 1 • 7:20 AM EDT • Science • today.uconn.edu
Wilmington Small Business Coalition: Building Momentum in 2026 by Heather McWhorter

This article was contributed by Lydia Thomas, UNCW CIE Program Manager. North Carolina continues to be one of the best states to start a business and in 2025, Wilmington, North Carolina earned a spot on the GoDaddy list of the top 10 most entrepreneurial cities in the U.S. While many know Wilmington as small beach town with exceptional food, lots of coffee shops, and fun, vibrant summer activities, a closer look reveals a thriving innovation economy. You’ll find startups emerging across industries including software, healthtech, bluetech, and fintech. At the core of this entrepreneurial ecosystem is the Wilmington Small Business Coalition, with small business advocates and entrepreneur support organizations (ESOs) dedicated to helping founders grow, thrive, and succeed. “No Wrong Door” Established in 2016, the Coalition was designed to make it easier for individuals and small businesses to access resources most suited to their particular needs. The Coalition is designed to have a “no wrong door” entryway into the regional startup ecosystem. Whether you are exploring a new idea sketched on the back of a napkin or leading a more established, growth-stage company, Coalition members can help connect you with the programs, funding opportunities, mentors, and resources best suited to your needs. No matter where you are in your entrepreneurial journey, any Coalition organization can help point you in the right direction. Coalition Members and Leadership Coalition members include the UNCW Center for Innovation and Entrepreneurship (UNCW CIE), AARP, Brunswick Community College Small Business Center, Cape Fear Community College Small Business Center, Cape Fear Region SCORE, Genesis Block Foundation, Network for Entrepreneurs in Wilmington (NEW), Small Business & Technology Development Center (SBTDC), Greater Wilmington Chamber of Commerce, YWCA Living the Dream Center for Entrepreneurship, Carolina Community Impact Fund (CCI Fund), Partner Community Capital, 717mkt Office Collaborative, NC Biotech, and Institute NC. In May 2026, the Coalition held its leadership elections, resulting in the selection of a new executive team. The following officers were elected to serve two-year terms: Chair: Lydia Thomas, UNCW CIE Vice Chair: Diane Lantz, CCI Fund Secretary: Aariene Hansley, Genesis Block Foundation Treasurer: Gloria Monroe, SBTDC Vision for the Wilmington Small Business Coalition In 2026, the Wilmington Small Business Coalition continues its work as a collaborative network of organizations. By connecting programs, expertise, and services across partner organizations, entrepreneurs can more easily find the right support at the right time. Rather than operating in silos, the Coalition aims to function as a unified, cohesive system of support for small businesses and entrepreneurs, ensuring that resources and expertise across partner organizations are visible and accessible. Through stronger collaboration and shared pathways, entrepreneurs can move more seamlessly from idea to startup to growth. Looking to dive into the Wilmington entrepreneurial ecosystem? Connect with any of the Coalition partners to get started! Connect with CIE To learn more about CIE and our services, programs, and events, join the CIE newsletter. You can also follow us on social media: Instagram, Facebook, LinkedIn, TikTok, or YouTube. CIE’s website is uncw.edu/cie. Heather McWhorter is the director of the UNCW Center for Innovation and Entrepreneurship (CIE). CIE supports innovation-forward start-ups and helps to build a vibrant innovation economy for all in southeast NC.

wilmingtonbiz.com logo
Jun 30 • 8:00 PM EDT • Business • wilmingtonbiz.com
Indy economic development leaders visiting Switzerland on trade trip

The trip will involve meetings with leaders in the life sciences, biotechnology and pharmaceuticals, medical technology, digital heath and advanced manufacturing sectors.

ibj.com logo
Jun 29 • 1:20 PM EDT • Business • ibj.com
Databricks and Nvidia Launch Genesis Workbench for AI Scientists

AI is becoming an increasingly important tool for drug discovery. However, for many pharmaceutical and biotech companies, the challenge isn’t finding more powerful models. It’s getting existing models to work […]

hpcwire.com logo
Jun 29 • 11:28 AM EDT • Science • hpcwire.com
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases

Oversubscribed $225 million concurrent private investment in public equity ("PIPE") with available cash to the combined company at closing anticipated to fund...

prnewswire.com logo
Jun 29 • 7:00 AM EDT • Business • prnewswire.com
Investor Clive Meanwell on designing biotechs for population health, and AI's role as a catalyst

Clive Meanwell, chairman of investment firm Population Health Partners, was an AI skeptic until recently. Now, he thinks it's a catalyst.

statnews.com logo
Jun 29 • 4:30 AM EDT • Health • statnews.com
AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs

Edison Scientific and investment firm Population Health Partners are teaming up to leverage AI agents in drug discovery and development.

statnews.com logo
Jun 29 • 12:30 AM EDT • Health • statnews.com
😐 Neutral (5%)
wow
100%
Germany's Merck to buy Bio-Techne for $11.3 billion

Merck ​KGaA ​has ​agreed to acquire biotech firm Bio-Techne for $11.3 billion, the ⁠German ‌science and healthcare ⁠firm said in a statement on Thursday.

cnbc.com logo
Jun 25 • 6:39 AM EDT • Science • cnbc.com
Germany's Merck to buy Bio-Techne for $73 per share

Merck KGaA has ​agreed to acquire ‌biotech firm Bio-Techne Corp ​for $73 per ​share in cash, ⁠the German ​science and ​healthcare firm said in a statement ​on ​Thursday.

reuters.com logo
Jun 25 • 6:09 AM EDT • Business • reuters.com
DolCas Biotech: CEO highlights Morikol marine collagen science and delivery format R&D
nutritioninsight.com logo
Jun 24 • 8:00 PM EDT • Science • nutritioninsight.com
The biotech founder asking why good science gets stuck

As an undergraduate, Alinta Furnell led student societies, pitched startup ideas and built biotechnology ventures. Now, the UNSW alumna is investigating one of innovation’s biggest challenges – why so many scientific breakthroughs never make it beyond the lab.

unsw.edu.au logo
Jun 24 • 7:00 PM EDT • Science • unsw.edu.au
Health Brief: FDA signals reset in drug reviews

Plus: The data behind China’s biotech surge

washingtonpost.com logo
Jun 22 • 7:02 PM EDT • Health • washingtonpost.com
Federal health agencies unveil plan to speed up phase 1 clinical trials by 6 to 12 months

As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of | As the biotech world flocks to San Diego today for the BIO International Convention, the Department of Health and Human Services has provided plenty of conversation fodder with the announcement of a series of efforts to regain ground on China’s surging early-stage clinical development capabilities.

fiercebiotech.com logo
Jun 22 • 12:10 PM EDT • Health • fiercebiotech.com
Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

scmp.com logo
Jun 20 • 9:30 PM EDT • Business • scmp.com
😐 Neutral (3%)
love
63%
ahah
37%
Philippe Pouletty: Turning Europe’s Life Science Startups Into World Leaders

The French investor and entrepreneur reveals how he is building biotech and medtech giants to compete with China and the U.S.

insideprecisionmedicine.com logo
Jun 17 • 9:11 AM EDT • Science • insideprecisionmedicine.com
Building Scientists in the AI Era

Stevens Institute of Technology’s newly launched AI in Biology and Chemistry Community helps students explore AI’s role in health care, biotech and ed-tech careers.

insidehighered.com logo
Jun 16 • 8:00 PM EDT • Science • insidehighered.com
How a biotech turned a trial failure into an AI model

In this edition of STAT Health Tech: How a biotech startup turned a failed clinical trial into an AI model, and more.

statnews.com logo
Jun 16 • 12:45 PM EDT • Health • statnews.com
😐 Neutral (0%)
love
100%
Adaptive plots splitting Pfizer-partnered drug discovery unit from diagnostics business

Adaptive Biotechnologies is planning to separate its drug discovery and diagnostics businesses,

fiercebiotech.com logo
Jun 16 • 9:24 AM EDT • Business • fiercebiotech.com
NMSU helps launch biotech game that lets students explore science careers

NMSU and UConn Extension developed a free 4-H biotech game that lets students explore 10 science careers through hands-on tasks.

organmountainnews.com logo
Jun 13 • 6:21 PM EDT • Science • organmountainnews.com
Heart Health Biotech Kardigan Seeks $373.3 Million in US IPO

Kardigan Inc. is seeking to raise $373.3 million in a US initial public offering to help fund three late-stage drugs that target cardiovascular diseases.

bloomberg.com logo
Jun 11 • 6:40 AM EDT • Health • bloomberg.com
A Newer Approach to Editing Embryos Ignites Debate

Fertility specialists, biotech companies and ethicists are divided over whether progress in early gene editing would wipe out diseases or trigger a rush toward enhancement.

nytimes.com logo
Jun 11 • 5:05 AM EDT • Science • nytimes.com
California wants to cap business tax credits, alarming life sciences and tech industries

California's life sciences industry, and some lawmakers, urge state leaders to reject budget proposal to permanently limit R&D tax credits.

calmatters.org logo
Jun 8 • 8:00 AM EDT • Business • calmatters.org
Human Research, Biotechnology for Advanced Health Fill Station Research Schedule

Wednesday’s science schedule aboard the International Space Station encompassed human research, microbial analysis, and 3D bioprinting to advance health on and off the Earth. The Expedition 74 crew members also worked on spacesuit maintenance and cargo spacecraft duties throughout the day rounding out their shift.

nasa.gov logo
Jun 3 • 4:17 PM EDT • Health • nasa.gov
Deep dive
😐 Neutral (11%)
wow
34%
ahah
33%
love
33%
Fulcrum tanks as cancer concerns stymie sickle cell asset, trigger business reorg

Fulcrum Therapeutics’ is down more than 50% Tuesday morning as the biotech discontinues development of its lead asset. Ipsen’s Tazverik, which belongs to the same class, was pulled from the market in March due to the risk of secondary malignancies.

biospace.com logo
Jun 2 • 8:19 AM EDT • Business • biospace.com
Are Chinese biotech firms an ally or an existential threat?

The question of whether to partner with Chinese firms — or see them as rivals — is tearing biotech apart.

bostonglobe.com logo
May 31 • 11:38 AM EDT • Business • bostonglobe.com
Deep dive
😐 Neutral (10%)
wow
39%
ahah
34%
love
27%
P2 Science Raises $23 Million to Produce Green Chemicals for Beauty, Personal Care Sectors

Biotechnology and green chemistry company P2 Science announced that it has raised $23 million in a new financing round, with proceeds aimed at accelerating its growth in the beauty and personal care ingredients market, and expanding its platform into new markets. Co-founded by Professor Paul Anastas and Dr. Patrick Foley at the Center for Green […]

esgtoday.com logo
May 28 • 4:18 AM EDT • Science • esgtoday.com
Ebola, chemical plants and health, hantavirus, common colds, heat and more

As they say, bugs have ears. Public health has had a relentless May. Chemical plant (near) explosions, Ebola, hantavirus, and that's before you even get to the usual suspects: common colds, heat, and ticks. Here’s an attempt to keep you up to speed and, more importantly, what it means for you and your community. But first, an announcement: World Cup The World Cup starts in 15 days (not like anyone is counting down), and we are hanging TVs in the Health Security Operations Center. It’s going to be a gorgeous, chaotic celebration of basically every culture on earth. And it’s going to take a team effort—from communities to individuals, from public health to health care—to keep people healthy. That’s where you come in. If you’re going to the games or live within 30 miles of a stadium, we would love to hear from you. Sign up for a weekly survey here. Thanks to the more than 1,280 people who have already signed up…you will be hearing from us soon!! Global disease “weather report” Hantavirus: Two more cases The global count of cruise ship passengers with hantavirus has now increased to 13 cases (11 confirmed), with three deaths. The two new cases are overseas and among people who were already quarantining: A crew member in the Netherlands. A Spanish national passenger who was quarantining at home tested positive through daily monitoring. They are now in a biocontainment unit. In the U.S., everyone remains negative. There may be more cases, given that the incubation period of hantavirus (the time from exposure to infection) is 45 days. But this week, we will reach a major milestone: the median incubation window is 18 days, and that will pass on May 29. What this means for you: Your risk from this cruise ship outbreak remains essentially nil at this point. Ebola rages on in Central Africa Big thanks to Dr. Craig Spencer, a humanitarian physician who has treated and survived Ebola, for jumping in to provide the YLE community with an update. Craig, take it from here… The combined confirmed and suspected Ebola cases in DRC are now more than 1,000. All signs are pointing to a very long and catastrophic outbreak in Central Africa: This is a vast undercount. We know this because the test positivity rate is hovering around 50%, only 20% of contacts are being traced (and in some areas, no contacts at all), and more cases keep popping up with no known connection. This all points to widespread and undetected community transmission. This is in only a week of detection. Compared to previous outbreaks, the growth is very fast, as the huge West Africa outbreak in 2016 was first detected at 49 cases and rose to 208 cases a month later. It took four months for that outbreak to reach the size of the current one in the DR Congo. The cases are spread out across 16 health zones. There are now multiple epicenters, making containment very difficult. Next door in Uganda, the case count is seven. While this number is low compared to DRC, a concerning development is that two health care workers recently tested positive with uncertain exposure histories. If they weren’t treating known Ebola cases, this means it’s spreading undetected in Uganda as well. On the ground, backlash, including the burning of health centers, has emerged, a pattern seen in nearly every outbreak and rooted in deep community distrust. It often stems from outside actors working in communities without fully understanding or addressing local priorities. Affected populations may recognize the severity of Ebola while still holding other concerns as more pressing, such as where their loved ones are buried. Community trust is essential to an effective response, but difficult to build during an active emergency. It is best established long before a crisis begins. U.S. priorities are made clear, and may backfire. The U.S. Administration has shown that its first priority is keeping Ebola out, with helping end the outbreak in the DRC a secondary concern. That's meant travel restrictions broader than anything we've imposed before — covering travelers from across the region, and reportedly some green card holders and permanent residents as well. For example, just these past two days, news broke that high-risk American travelers will be subject to a mandatory quarantine in Kenya before they are allowed to return. If an American is infected, the U.S. government plans to send them to a hospital it is standing up from scratch in Kenya. (Currently, Americans who were in the area are allowed to return but are diverted to three airports—Houston, Atlanta, and DC—for further screening.) Past administrations have used travel notices and stepped-up screening; this goes much further. At first blush, these strict precautions may sound prudent. But this approach could backfire in three ways: Restrictions this blunt give people every reason to hide where they’ve been and whom they’ve been near — making the people we most need to find harder to track, not easier. They also breed a false sense that this is someone else’s problem. But diseases are humbling. They find the small cracks in even the most impenetrable-seeming defenses. Lives lost. There is no treatment for this Ebola strain, which means survival depends heavily on the quality of the health system. We have that system in the States, but we are choosing not to use it for infected Americans. This is unbelievable and infuriating. (See a deeper dive from me here.) The only real way to lower the risk to Americans — and everyone else — is to end the outbreak in the DRC and across the region. What this means for you: If you have travel plans to this region, it’s time to cancel them. This is a high-risk situation in Central Africa, and CDC released a Level 4 Travel Advisory. There is also great uncertainty if and when the Administration will let you back in. To the general public in the U.S., your risk remains very, very low right now. U.S. disease “weather report” Ticks: past peak season? Good news, especially for people in the Northeast and Midwest: tick numbers continue to decline. Though we are at the peak of the season, this unusually early year is trending favorably. Heat-related illnesses in the North Heat risk is certainly not blanketing the entire country yet, but this week it will be moderate in the Midwest and the Southeast. What this means for you: Be sure to check the CDC HeatRisk tool. A red day isn’t the best day for that soccer game for a kid with asthma, and a stretch of orange days is a great time to check on your elderly neighbor. Common colds surging As far as respiratory viruses go, the only thing really going around right now is the common cold. It is higher this year than last year, but should peak very soon before returning this fall. Spotlight: Chemical plants Over the weekend, YLE California covered the serious situation that unfolded around a chemical plant in Orange County, California. Thankfully, the worst-case scenario (a chemical explosion) was mitigated, but only through luck. The health implications in a densely populated area could have been catastrophic. As the situation was winding down, another chemical explosion struck Washington State. This one was fatal. Health officials say the risk to surrounding residents from chemicals in the air and ground remains low, though the community deserves far greater clarity. Clean air and clean water consistently rank as Americans’ top public health concerns — yet when chemical disasters strike, communities are too often met with reassurances rather than transparency and accountability. Residents near the 2023 East Palestine, Ohio train derailment, for example, are still waiting to understand the long-term impact on their health, with few clear answers. What this means for you: Many are wondering if facilities processing potentially dangerous materials are in their neighborhoods. This interactive map allows you to enter your ZIP code and see all facilities monitored by the EPA, including any violations. Good news Ebola vaccines and treatment for the Bundibugyo species are in development. Two vaccine platforms are being explored, at least one of which may be deployable in as little as 2 months. One vaccine is being developed by Oxford, and the other uses the same biotechnology as the FDA-approved Zaire species of Ebola. (It may provide cross-protection, but it’s unclear at this point.) On the treatment side, two promising monoclonal antibody cocktails are likely to be deployed, though doses are limited and logistical hurdles remain significant challenges. Anni over at The Biotech Tea had a great explainer about the Ebola vaccine gap, if you want to read more. [ The Biotech Tea The Ebola vaccine gap, reading vessel damage, & the Makary exit 🗝️ Paid subscribers get the Biotech Term of the Week at $30/year (~$2.50/month). I try to keep it intentionally accessible, but if cost is ever a barrier, send me a message. A few people asked about expensing your subscription, so I put together a short email template… Read more 6 days ago · 10 likes · Annicka Evans, PhD ](https://www.thebiotechtea.com/p/the-ebola-vaccine-gap-reading-vessel?utm_source=substack&utm_campaign=post_embed&utm_medium=web) Polycystic ovary syndrome (PCOS) has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS), following more than a decade of debate and input from roughly 22,000 clinicians, researchers, and patients worldwide. This is good because the old name was medically misleading, leading to patients without visible cysts being dismissed or overlooked entirely. The WHO estimates that 70% of people with the condition remain undiagnosed. A more accurate name should improve recognition, reduce stigma, and ultimately help the millions of people living with this condition get diagnosed and treated sooner. Poll Loading... Bottom line Public health situations are everywhere right now. Staying healthy takes public health professionals and systems working tirelessly behind the scenes and each of us showing up for our neighbors and communities. Love, YLE Big thanks to Ed Nirenberg for staying on top of the Ebola vaccines, Hannah Totte for all the figures, Dr. Craig Spencer for the Ebola insight, and Dr. Matt Willis for covering the chemical situation in CA. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “Translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe

yourlocalepidemiologist.substack.com logo
May 27 • 7:43 AM EDT • Health • yourlocalepidemiologist.substack.com
Robotics, Science Underway as Cosmonauts Prep for Wednesday Spacewalk

Robotics controllers wrapped up a weekend of swapping scientific hardware packed inside the SpaceX Dragon cargo spacecraft’s trunk for installation on the International Space Station. Meanwhile, the Expedition 74 crew is continuing its biotechnology and botany research while getting ready for a spacewalk scheduled for Wednesday, May 27.

nasa.gov logo
May 26 • 2:04 PM EDT • Science • nasa.gov
Breeding Possibilities for Better Crops

Driven by a strong work ethic, Caitlin Kestell, a doctoral student in crop science, pursues genome editing and biotechnology to advance crop improvement and inspire young scientists.

cals.ncsu.edu logo
May 26 • 8:24 AM EDT • Science • cals.ncsu.edu
Deep dive
😐 Neutral (18%)
love
44%
wow
30%
ahah
26%
A de-extinction company has hatched live chicks from an artificial eggshell

A biotech company that aims to resurrect lost creatures says it has hatched live chicks in an artificial environment

latimes.com logo
May 23 • 8:00 AM EDT • Science • latimes.com
A chemical found in fish could help reinvent your sunscreen

It’s been over 25 years since the FDA approved a new ingredient for sunscreen in the United States. But a molecule called gadusol found in fish and coral reefs is a promising candidate. It absorbs U.V. rays — acting like a built-in sunscreen for fish. But there’s a big hurdle if scientists want to turn gadusol into human sunscreen: They’d need to make a lot of it. A new study out this week in the journal Trends in Biotechnology takes us a big step closer. Their solution? Using the bacteria best known for making your stomach hurt: e. Coli. Interested in more science? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.

npr.org logo
May 15 • 3:00 AM EDT • Science • npr.org
High-Signal Publisher
AI Life Science Firm Metis TechBio Set for HK Debut After IPO

Metis TechBio Co, a biotechnology company using artificial intelligence to deliver and formulate drugs, is set to begin trading in Hong Kong after raising HK$2.1 billion ($270 million) in an initial public offering.

bloomberg.com logo
May 12 • 7:00 PM EDT • Science • bloomberg.com
Curis Provides First Quarter 2026 Business Update

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule...

prnewswire.com logo
May 12 • 4:00 PM EDT • Business • prnewswire.com
How jellyfish bycatch could be valuable collagen source for cosmetics and biotech

Dr Ainara Ballesteros is a Juan de la Cierva postdoctoral researcher at the Institute of Environment and Marine Science Research at the Catholic University of Valencia, where she leads a research group focused on jellyfish biology, aquaculture, and the sustainable use of marine resources. Her work is centered on developing innovative solutions based on marine science, particularly through the study of underused organisms as sources of high-value compounds within circular bioeconomy and zero-waste strategies. She is joined in this work by Raquel Torres, a PhD student at the same institute, who is carrying out her doctoral thesis within this line of research, focused on jellyfish valorization, collaboration with the fishing sector, and the sustainable management of marine resources. They are co-authors on a new Frontiers in Marine Science article which investigated whether jellyfish accidentally caught by small-scale fishers in Spain could be transformed into a valuable resource instead of being treated as waste. The team worked side by side with fishers to better understand their perceptions of jellyfish bycatch, identify which species are most frequently caught, and evaluate whether one of them, Rhizostoma pulmo, could serve as a sustainable source of high-quality collagen.

eurekalert.org logo
May 10 • 8:00 PM EDT • Science • eurekalert.org
ORNL names Kate Evans associate lab director for biological, environmental systems science

The Department of Energy’s Oak Ridge National Laboratory has named Katherine (Kate) Evans as associate laboratory director for the Biological and Environmental Systems Science Directorate (BESSD). Evans will lead the directorate as it advances the science and technology needed to strengthen energy security, safeguard infrastructure and accelerate biotechnology innovation.

newswise.com logo
May 8 • 12:55 PM EDT • Science • newswise.com
ORNL names Kate Evans associate lab director for biological, environmental systems science

The Department of Energy’s Oak Ridge National Laboratory has named Katherine (Kate) Evans as associate laboratory director for the Biological and Environmental Systems Science Directorate (BESSD). Evans will lead the directorate as it advances the science and technology needed to strengthen energy security, safeguard infrastructure and accelerate biotechnology innovation.

eurekalert.org logo
May 8 • 8:00 AM EDT • Science • eurekalert.org
MARY BRUNKOW

A chance discovery made around 80 years ago paved the way for Mary Brunkow’s painstaking work, which contributed to redefining how the immune system functions. From investigating an obscure gene dismissed as ‘junk’ by other scientists, to choosing to opt out of academia and conduct her research at a biotech startup, Brunkow has embraced the unexpected throughout her career.

nobelprize.org logo
May 8 • 4:41 AM EDT • Science • nobelprize.org
Thymus renaissance poised to boost health and longevity

Nature Biotechnology - Evidence linking thymic function with health and longevity is piling up, and a cluster of biotechnology companies is trying to regenerate the thymus directly or recapitulate...

nature.com logo
May 4 • 8:00 PM EDT • Health • nature.com